OrbiMed’s AstraZeneca AZN Stock Holding History

OrbiMed’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$171M	Buy	915,700 +245,500	+37%	+$46.2M	3.17%	6
2026 Q1	$132M	Buy	+670,200	New	+$129M	2.62%	9
2020 Q1	–	Sell	-34,800	Closed	-$3.47M	–	147
2019 Q4	$3.47M	Buy	+34,800	New	+$3.28M	0.05%	110

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed's AZN Position: Q2 2026 in Review

OrbiMed increased its AstraZeneca (AZN) stake by 37% in Q2 2026, buying an estimated $46.2M and bringing the position to 915,700 shares worth $171M. The position accounts for 3.17% of the portfolio, ranked #6.

OrbiMed first reported a position in AZN in Q4 2019 and has held it in 3 quarters since. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

OrbiMed held 915,700 shares of AstraZeneca worth $171M as of Q2 2026.
OrbiMed bought 245,500 AstraZeneca shares in Q2 2026, an estimated $46.2M.
AstraZeneca made up 3.17% of OrbiMed's portfolio in Q2 2026, its #6 holding.
OrbiMed first reported a position in AstraZeneca in Q4 2019 and has held it in 3 quarters since.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.